Contribute Try STAT+ Today

Bayer, the German drug and agriculture conglomerate, is purchasing an under-the-rader gene therapy firm for as much as $4 billion.

The firm, Asklepios Biopharmaceutical, is widely known as AskBio and has existed for 20 years as the vehicle for commercializing the work of its chief scientific officer, Richard Jude Samulski, one of gene therapy’s pioneers. AskBio, based in Research Triangle Park in North Carolina, was founded in 2001 based on technology Samulski started working on as a graduate student.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy